Symptom burden of patients with moderate-to-severe atopic dermatitis

Egeberg, Alexander; Anderson, Peter; Piercy, James; Massey, Lucy; Cappelleri, Joseph C.; Encinas, Gerardo A; Feeney, Claire; DiBonaventura, Marco

doi:10.1684/ejd.2021.4166

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The negative impact of itching has already been observed in a wide spectrum of dermatological conditions both in adults and in children [55][56][57][58][59][60]. In eczematous diseases, it represents the symptom with the greatest impact on QoL [61]. Itching can negatively affect sleep and to a lesser extent sexual desire and appetite.…”

Section: Discussionmentioning

confidence: 99%

Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands

et al. 2023

View full text Add to dashboard Cite

Background: quality of life (QoL) impairment by eczematous diseases, with reference to body site involvement, has not been deeply addressed; Objectives: to assess: i) the impact on QoL of eczematous diseases affecting the face or hands; ii) any differences in QoL impairment in the case of face versus hands involvement; iii) sensitivity of Pictorial Representation of Illness and Self-Measure (PRISM) and Dermatology Life Quality Index (DLQI) in measuring disease-related burden; Methods: adults with eczematous diseases of the face or hands were involved. Patients were patch tested and underwent DLQI and PRISM; Results: 143 patients were included, 43.36% with face and 56.64% with hands involvement. PRISM and DLQI scores showed a moderate-to-strong inverse correlation, but PRISM revealed a higher sensitivity in capturing patients’ suffering than DLQI, especially in the case of face involvement. Itching was the sole parameter significantly associated with both PRISM and DLQI scores. Conclusions: PRISM appeared to be more accurate in detecting the burden of eczematous diseases involving the face, probably due to the interception of the emotional impact, while DLQI, focusing on patient functioning, was more affected by hands involvement. Site involvement could be a criterion for selecting the best QoL assessment tool.

show abstract

Section: Discussionmentioning

confidence: 99%

Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In daily practice, many patients complain of skin discomfort, which may improve with dupilumab. 8 It has also been reported that improvement in symptoms leads to treatment satisfaction. 9 Therefore, we added uncomfortable skin-NRS and treatment satisfaction-NRS to the clinical outcomes as PROs in our evaluation.…”

Section: Exploring Biomarkers To Predict Clinical Improvement Of Atop...mentioning

confidence: 97%

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B‐PAD study)

Nakahara

Izuhara

Onozuka

et al. 2022

Clin Experimental Allergy

View full text Add to dashboard Cite

“…Reactive treatment of AD usually involves corticosteroids and/or calcineurin inhibitors [15]. Symptomatic AD and higher AD severity was shown to have a negative impact on various aspects of patients' quality of life [16,17].…”

Section: Atopic Dermatitismentioning

confidence: 99%

Topical proactive therapy in dermatology. A scoping review

Makowska,

Nowaczyk,

Samochocki

et al. 2023

pdia

View full text Add to dashboard Cite

The term 'proactive therapy' refers to a long-term management of clinically intact skin in previously disease-affected areas. This method was initially implemented in atopic dermatitis to maintain the remission and decrease the risk of exacerbations. Proactive therapy aims to limit the need for reactive treatment and improve the patients' quality of life. A proactive approach is likely to be adopted for other relapsing and inflammatory skin conditions in the future. This scoping review aims to identify dermatological conditions to be treated with the proactive approach, evaluate the available evidence for its efficacy and safety, as well as highlight the research gaps.

show abstract

Symptom burden of patients with moderate-to-severe atopic dermatitis

Cited by 9 publications

References 0 publications

Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands

Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B‐PAD study)

Topical proactive therapy in dermatology. A scoping review

Contact Info

Product

Resources

About